This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Dupixent
  • /
  • Study in Pediatric Subjects With Peanut Allergy to...
Clinical trial

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Read time: 1 mins
Last updated:9th Mar 2021
Status: Active, not recruiting
Identifier: NCT03682770
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)


Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16.

Secondary objectives are:
- To assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the cumulative tolerated dose (log transformed) of peanut protein during a post up-dosing DBPCFC at visit 16
- To assess whether dupilumab as (indefinite [continuously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
- To assess whether dupilumab as (limited [previously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
- To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to placebo
- To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G (IgG), Immunoglobulin G4 (IgG4), and peanut-specific IgG4/IgE ratio
- To assess if dupilumab increases the tolerability of AR101 as measured by the daily symptoms (electronic diary [e-diary]) during the up-dosing phase.


Study Type: Interventional (Clinical Trial)
Actual Enrollment: 149 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Actual Study Start Date: October 3, 2018
Actual Primary Completion Date: October 16, 2020
Estimated Study Completion Date: October 6, 2021

Arm:
- Experimental: dupilumab + AR101
- Experimental: placebo matching dupilumab + AR101


Category Value
Study type(s) Interventional
Actual enrolment 149
Actual Study start date 03 October 2018
Estimated Study Completion Date 06 October 2021

View full details